Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 1296Carcinoma, Non-Small-Cell Lung 793Neoplasms 787Colorectal Neoplasms 762Stomach Neoplasms 588Carcinoma, Hepatocellular 581Prostatic Neoplasms 514Lung Neoplasms 466Pancreatic Neoplasms 421Rectal Neoplasms 336Recurrence 315Neoplasm Metastasis 310Leukemia, Myeloid, Acute 293Colonic Neoplasms 283Multiple Myeloma 281Lymphoma 276Esophageal Neoplasms 273Uterine Cervical Neoplasms 272Ovarian Neoplasms 263Melanoma 246Head and Neck Neoplasms 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 210Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 187Nasopharyngeal Carcinoma 182Leukemia 173Lymphoma, Non-Hodgkin 172Liver Neoplasms 165Glioblastoma 160Polycystic Ovary Syndrome 157

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Interventional × Nonsquamous Non-small Cell Lung Cancer × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡